FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2153-2155 November 16, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fowler, V. G. Related Article by Moran, G. J.

To the Editor: In the study by Fowler et al. (Aug. 17 issue),¹ the standard therapy for Staphylococcus aureus infection is not a homogeneous entity. One cannot compare a new drug (daptomycin) with a mixture of two regimens (vancomycin or an antistaphylococcal penicillin) when the first regimen is reported to be considerably inferior to the other.^2,3 Although Table 2 of the article lists success rates according to the susceptibility of S. aureus to methicillin, a breakdown in success rates according to the receipt of vancomycin or an antistaphylococcal penicillin is lacking. Patients with methicillin-susceptible S. aureus (MSSA) infections could have . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.